Categories AlphaGraphs, Earnings, Technology

Earnings: Here’s everything you need to know about Microsoft’s Q4 results

Microsoft Corp. (NASDAQ: MSFT) on Tuesday reported financial results for the fourth quarter of 2023. The tech giant’s cloud business continued to expand during the period.

Microsoft Q4 2023 earnings infographic

The company reported fourth-quarter revenues of $56.2 billion, compared to $51.9 billion in the same period of 2022. Net profit came in at $20.08 billion or $2.69 per share in the June quarter, vs. $16.74 billion or $2.23 per share in the comparable period of last year.

“We remain focused on leading the new AI platform shift, helping customers use the Microsoft Cloud to get the most value out of their digital spend, and driving operating leverage,” said Microsoft’s CEO Satya Nadella.

Prior Performance

  • Microsoft Q2 2023 earnings infographic
  • Microsoft Q1 2023 earnings infographic
  • Microsoft Q4 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top